Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy.
We have previously shown that mechanical stress induces activation of protein kinases and increases in specific gene expression and protein synthesis in cardiac myocytes, all of which are similar to those evoked by humoral factors such as growth factors and hormones. Many lines of evidence have suggested that angiotensin II (Ang II) plays a vital role in cardiac hypertrophy, and it has been reported that secretion of Ang II from cultured cardiac myocytes was induced by mechanical stretch. To examine the role of Ang II in mechanical stress-induced cardiac hypertrophy, we stretched neonatal rat cardiac myocytes in the absence or presence of the Ang II receptor antagonists saralasin (an antagonist of both type 1 and type 2 receptors), CV-11974 (a type 1 receptor-specific antagonist), and PD123319 (a type 2 receptor-specific antagonist). Stretching cardiac myocytes by 20% using deformable silicone dishes rapidly increased the activities of mitogen-activated protein (MAP) kinase kinase activators and MAP kinases. Both saralasin and CV-11974 partially inhibited the stretch-induced increases in the activities of both kinases, whereas PD123319 showed no inhibitory effects. Stretching cardiac myocytes increased amino acid incorporation, which was also inhibited by approximately 70% with the pretreatment by saralasin or CV-11974. When the culture medium conditioned by stretching cardiocytes was transferred to nonstretched cardiac myocytes, the increase in MAP kinase activity was observed, and this increase was completely suppressed by saralasin or CV-11974. These results suggest that Ang II plays an important role in mechanical stress-induced cardiac hypertrophy and that there are also other (possibly nonsecretory) factors to induce hypertrophic responses.
Yamazaki
T
T
Third Department of Internal Medicine, University of Tokyo School of Medicine, Tokyo, Japan.
Komuro
I
I
Kudoh
S
S
Zou
Y
Y
Shiojima
I
I
Mizuno
T
T
Takano
H
H
Hiroi
Y
Y
Ueki
K
K
Tobe
K
K
D000804:Angiotensin II / Q000187:drug effects / Q000502:physiology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D006332:Cardiomegaly / Q000201:enzymology / Q000378:metabolism / Q000503:physiopathology*; D002478:Cells, Cultured; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation; D020929:Mitogen-Activated Protein Kinase Kinases; D009206:Myocardium / Q000166:cytology / Q000201:enzymology / Q000378:metabolism; D010649:Phenylalanine / Q000378:metabolism; D011494:Protein Kinases / Q000032:analysis / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011945:Receptors, Angiotensin / Q000378:metabolism / Q000502:physiology; D012504:Saralasin / Q000494:pharmacology; D015398:Signal Transduction; D013314:Stress, Mechanical; D013777:Tetrazoles / Q000494:pharmacology
D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D000804:Angiotensin II; D010649:Phenylalanine; D011494:Protein Kinases; D020929:Mitogen-Activated Protein Kinase Kinases; D012504:Saralasin; C081643:candesartan